Molecular Quality Controls Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Molecular Quality Controls Market

Molecular Quality Controls Market Product (Independent Control, Instrument Specific Control (PCR, DNA Sequencing), Application (Infectious Disease Diagnostics), Analyte type, End User (Hospitals, Diagnostic Lab), Region- Global Forecast to 2028

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 6900 Jul, 2023, by marketsandmarkets.com

The global molecular quality controls market in terms of revenue was estimated to be worth $0.2 billion in 2023 and is poised to reach $0.3 billion by 2028, growing at a CAGR of 6.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is primarily driven by the increasing number of accredited clinical laboratories, growing adoption of third-party quality controls, and increasing government funding for genomic projects. Rising demand for multi-analyte controls and growth opportunities in emerging countries are expected to offer opportunities for market players during the forecast period.

On the other hand, the additional costs involved in the quality control process and budget constraints in hospitals and laboratories, are expected to restrain the market growth to some extent in the coming years.

Global Molecular Quality Controls  Market Trends

Molecular Quality Controls Market

To know about the assumptions considered for the study, Request for Free Sample Report

Molecular Quality Controls Market

Molecular Quality Controls Market Dynamics

Driver: Growing preference for personalized medicines

Genomics has played a key role in the emergence of personalized medicine. Personalized medicine provides tailored treatments and prevention procedures to suit each individual’s condition for optimal results. This field of medicine offers the most promising approach to tackle diseases that have not been well-known for responding effectively to the existing treatments or cures. As per the Personalized Medicine report published in the PMC (Personalized Medicine Coalition):

  • In 2022, FDA’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), among these two NMEs were therapeutic products and others were diagnostic agents. 12 of the 35 new therapeutic molecular entities approved by the US FDA and 5 new cell-based therapies were personalized medicine.

The cost of genome sequencing has dropped dramatically in the last six years, approximately a million-fold. The Human Genome Project was completed by thousands of researchers in 13 years and cost USD 2.7 billion (Source: WIRED, September 2022). According to a blog published in Sequencing in 2022, due to the growing interest in DNA sequencing numerous bioinformatics companies are focused on creating new technologies, sequencers, and consumables aiming to offer genetic testing at affordable costs.

Restraint: Budgetary constraints in clinical laboratories

Setting up a QC process in a clinical laboratory requires significant investments. Laboratories also need to maintain dedicated personnel to manage the QC system. Moreover, QC procedures incur similar costs, regardless of the volume of tests performed. Hence, the cost of adopting QC procedures is very high for clinical laboratories working with low volumes of diagnostic tests. This, coupled with budgetary constraints in many hospitals and laboratories in developed and developing economies, is expected to result in the lower adoption of QC practices.

Opportunity: Rising demand for multi-analyte controls

Technological advancements have led to the development of a new range of multi-analyte and multi-instrument controls. These innovative controls consolidate multiple instrument-specific controls into a single control, thereby enabling clinical laboratories to cut down costs. In addition, these controls save the time involved in separate QC procedures for each individual analyte. A number of multi-analyte controls are available in the market, such as the Amplicheck Series (BD Company), AcroMetrix Series (Thermo Fisher Scientific), Seraseq Controls (SeraCare), and Introl Series (Maine Molecular Quality Controls). These controls help laboratories to perform quality control for multiple parameters, including cardiac and tumor markers and DNA/RNA of multiple infectious disease-causing agents in a single run.

Challenge: Stringent regulatory requirements for IVD products

Regulatory and legal requirements applied to IVD (including molecular diagnostics) in the US and European countries are becoming more stringent. In the US, IVD products are defined under 21 CFR 809 and regulated under guidelines like medical devices. The FDA released new FDA guidance documents. Under US federal regulations, device manufacturers must submit a 510 (k) application for any further modifications to a device. New applications may require software updates or new software installation in an existing device or any other changes made to these devices. In the past few years, the FDA requirements, particularly with regard to 510(k) notifications, have increased, requiring more data and details than earlier. This change, resulting in unpredictable premarket submission requirements, is extremely unfavorable for IVD manufacturers that require 510(k) clearance.

Molecular Quality Controls Market Ecosystem Map

Molecular Quality Controls Market Ecosystem

The independent controls segment of the Molecular Quality Controls Industry has accounted for the highest market share during the forecast period

On the basis of product, the molecular quality controls market is segmented into instrument specific controls and independent controls. The independent controls segment accounted for the highest share  of the global market in 2022. The large share of this segment is attributed to the longer shelf-life and reduced cost of operation.

The single-analyte controls has accounted for the highest share of the Molecular Quality Controls Industry during the forecast period.

Based on analyte type, the molecular quality controls market is segmented into multi-analyte controls and single-analyte controls. Single-analyte controls accounted for the highest share of the market in 2022. The large share of this segment can be attributed to the low risk of cross-reactivity and the significant use of singleplex assays in hospitals.

The infectious disease diagnostic segment accounted for the highest share of the Molecular Quality Controls Industry in 2022

On the basis of application, the molecular quality controls market is segmented into genetic testing, oncology testing, infectious disease diagnostics, and other applications (including microbiology, tissue typing, DNA fingerprinting, cardiovascular disease testing and neurology disease testing). The infectious disease diagnostics segment accounted for the highest share of the global market in 2022. The large share of this segment is attributed to the development of advanced assays for different infectious diseases.

The diagnostic laboratories segment accounted for the largest share of the Molecular Quality Controls Industry in 2022

Based on end users, the molecular quality controls market is segmented into diagnostic laboratories, hospitals, IVD manufacturers & CROs, academic & research institutes, and other end users (blood banks, local public health laboratories, home health agencies, and nursing homes). The diagnostic laboratories segment accounted for the largest share of the market in 2022. This can be attributed to the increasing number of accredited diagnostic laboratories worldwide and the growing number of laboratory tests performed in diagnostic laboratories.

North America accounted for the largest share of the Molecular Quality Controls Industry in 2022

Based on region, the molecular quality controls market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the market in 2022. The large share of this regional segment is mainly due to the developed healthcare system in the US and Canada and the presence of many leading molecular quality control product manufacturers.

Molecular Quality Controls Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US),  Bio-Rad Laboratories, Inc. (US), Anchor Molecular (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott Laboratories (US), Fortress Diagnostics (UK), SERO AS (Norway), Anchor Molecular (US), Vircell S.L. (Spain), Ortho Clinical Diagnostics, Inc. (US), QuidelOrthoCorporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix, LLC (US), Qnostics (UK), Bio-Techne Corporation (US), Microbiologics, Inc. (US), Steck LLC (US), Helena Laboratories Corporation (US), Microbix Biosystems Inc. (Canada), Molbio Diagnostics Pvt. Ltd. (India), SpeeDx Pty. Ltd. (Australia), Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).

Scope of the Molecular Quality Controls Industry

Report Metric 

Details 

Market Revenue in 2023

$0.2 billion

Projected Revenue by 2028

$0.3 billion

Revenue Rate

Poised to Grow at a CAGR of 6.6%

Market Driver

Growing preference for personalized medicines

Market Opportunity

Rising demand for multi-analyte controls

This study categorizes the global molecular quality controls market to forecast revenue and analyze trends in each of the following submarkets

By Product

  • INDEPENDENT CONTROLS
  • INSTRUMENT-SPECIFIC CONTROLS
    • POLYMERASE CHAIN REACTION (PCR)
    • DNA SEQUENCING & NGS
    • OTHER TECHNOLOGIES

By Analyte Type

  • SINGLE-ANALYTE CONTROLS
  • MULTI-ANALYTE CONTROLS

By Application

  • INFECTIOUS DISEASE DIAGNOSTICS
  • ONCOLOGY TESTING
  • GENETIC TESTING
  • OTHER APPLICATIONS

By End User

  • DIAGNOSTIC LABORATORIES
  • HOSPITALS
  • IVD MANUFACTURERS & CONTRACT RESEARCH ORGANIZATIONS
  • ACADEMIC & RESEARCH INSTITUTES
  • OTHER END USERS

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of APAC (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments of Molecular Quality Controls Industry

  • In 2023, Thermo Fisher Scientific (US) acquired The Binding Site Group to expands the company’s existing specialty diagnostics portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.
  • In 2022, Microbiologics Inc. (US) acquired the Cryologics (US) to extend the company’s capacity to serve quality control microbiologists dedicated to the safety of pharmaceutical and personal care products.
  • In 2021, LGC SeraCare expanded its line of SARS-CoV-2 molecular quality solutions to include AccuPlex SARS-CoV-2 Variant Panel 1.
  • In 2020, Roche entered a 15-year non-exclusive partnership with Illumina to broaden the adoption of NGS-based testing in oncology.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 24)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
          TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 STUDY LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
    2.2 RESEARCH DESIGN 
           2.2.1 SECONDARY RESEARCH
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY RESEARCH
                    FIGURE 2 PRIMARY SOURCES
                    2.2.2.1 Key data from primary sources
                                FIGURE 3 INSIGHTS FROM INDUSTRY EXPERTS
                    2.2.2.2 Breakdown of primaries
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 6 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS
          FIGURE 7 MARKET SIZE ESTIMATION: PARENT MARKET
          FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
          FIGURE 9 MOLECULAR QUALITY CONTROLS INDUSTRY: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS 
    2.6 STUDY ASSUMPTIONS 
    2.7 RISK ASSESSMENT 
          TABLE 2 MARKET: RISK ASSESSMENT ANALYSIS
    2.8 MARKET LIMITATIONS 
           2.8.1 METHODOLOGY-RELATED LIMITATIONS
           2.8.2 SCOPE-RELATED LIMITATIONS
    2.9 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 11 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,  2023 VS. 2028 (USD MILLION)
    FIGURE 12 MOLECULAR QUALITY CONTROLS INDUSTRY, BY ANALYTE TYPE,  2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY APPLICATION,  2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY END USER,  2023 VS. 2028 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 MOLECULAR QUALITY CONTROLS MARKET OVERVIEW 
          FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET
    4.2 MOLECULAR QUALITY CONTROLS INDUSTRY, BY PRODUCT 
          FIGURE 17 INSTRUMENT-SPECIFIC CONTROLS SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
    4.3 ASIA PACIFIC: MARKET,  BY APPLICATION AND COUNTRY 
          FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT IN JAPAN ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.4 MARKET: GEOGRAPHICAL MIX 
          FIGURE 19 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
    4.5 MARKET:  DEVELOPED MARKETS VS. EMERGING MARKETS 
          FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION 
          FIGURE 21 MOLECULAR QUALITY CONTROLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.1.1 DRIVERS
                    5.1.1.1 Rising number of accredited clinical laboratories
                                FIGURE 22 NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023)
                    5.1.1.2 Growing adoption of third-party quality controls
                                TABLE 3 THIRD-PARTY INDEPENDENT QUALITY CONTROLS OFFERED BY KEY COMPANIES
                    5.1.1.3 Increasing investments in genomics
                                TABLE 4 GOVERNMENT FUNDING INITIATIVES FOR GENOMICS RESEARCH (2019−2022)
                    5.1.1.4 Growing preference for personalized medicine
                                TABLE 5 US: NUMBER OF PERSONALIZED MEDICINES AVAILABLE (2008–2020)
                                FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES (2015–2022)
                                FIGURE 24 COST OF SEQUENCING PROCEDURES (2016−2021)
                    5.1.1.5 Increasing prevalence of infectious diseases and cancer
                                FIGURE 25 GLOBAL CANCER INCIDENCE, 2018–2040 (MILLION)
                    5.1.1.6 Rising demand for external quality assessment support
           5.1.2 RESTRAINTS
                    5.1.2.1 Budgetary constraints in clinical laboratories
                    5.1.2.2 Unfavorable reimbursements for molecular tests
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Rising demand for multi-analyte controls
                    5.1.3.2 Growth opportunities in emerging markets
           5.1.4 CHALLENGES
                    5.1.4.1 Stringent regulatory requirements for IVD products
    5.2 INDUSTRY TRENDS 
           5.2.1 LYOPHILIZED/FREEZE-DRIED CONTROLS
                    TABLE 6 LYOPHILIZED OR FREEZE-DRIED QUALITY CONTROLS OFFERED BY KEY COMPANIES
    5.3 PRICING ANALYSIS 
          TABLE 7 PRICE RANGE FOR MOLECULAR QUALITY CONTROLS, BY TYPE (2022)
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 26 VALUE CHAIN ANALYSIS
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 27 SUPPLY CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 28 MARKET: ECOSYSTEM MARKET MAP
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
           5.7.2 THREAT OF SUBSTITUTES
           5.7.3 BARGAINING POWER OF BUYERS
           5.7.4 BARGAINING POWER OF SUPPLIERS
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    5.8 TRADE ANALYSIS 
           5.8.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
                    5.8.1.1 Import data for diagnostic & laboratory reagents, by country, 2018–2021 (USD million)
                    5.8.1.2 Export data for diagnostic & laboratory reagents, by country, 2018–2021 (USD million)
    5.9 TARIFF AND REGULATORY ANALYSIS 
           5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.2 REGULATORY ANALYSIS
                    5.9.2.1 North America
                               5.9.2.1.1 US
                                              TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION
                                              TABLE 11 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL
                                              TABLE 12 US: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION
                               5.9.2.1.2 Canada
                                              TABLE 13 CANADA: CLASSIFICATION OF IVD PRODUCTS
                                              TABLE 14 CANADA: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION
                    5.9.2.2 Europe
                                TABLE 15 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES
                    5.9.2.3 Asia Pacific
                               5.9.2.3.1 Japan
                               5.9.2.3.2 China
                               5.9.2.3.3 India
    5.10 PATENT ANALYSIS 
           5.10.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
                     FIGURE 29 MARKET: TOP PATENT OWNERS AND APPLICANTS (JANUARY 2011–JUNE 2023)
                     FIGURE 30 MARKET: TOP APPLICANT JURISDICTIONS (JANUARY 2011–JUNE 2023)
           5.10.2 PATENT PUBLICATION TRENDS
                     FIGURE 31 MARKET: PATENT ANALYSIS (JANUARY 2011–FEBRUARY 2023)
                     TABLE 16 MARKET: LIST OF PATENTS/PATENT APPLICATIONS (2020–2023)
    5.11 KEY CONFERENCES AND EVENTS 
           TABLE 17 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS
                     TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS (%)
           5.12.2 BUYING CRITERIA
                     FIGURE 33 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS
                     TABLE 19 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS
    5.13 TRENDS AND DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES 
           FIGURE 34 MARKET: REVENUE SHIFT
 
6 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT (Page No. - 84)
    6.1 INTRODUCTION 
          TABLE 20 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS
          TABLE 21 MOLECULAR QUALITY CONTROLS INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 INDEPENDENT CONTROLS 
           6.2.1 MINIMIZED LOT CROSSOVERS FOR LABORATORIES AND LOW OPERATION COSTS TO DRIVE MARKET
                    TABLE 22 INDEPENDENT MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS
                    TABLE 23 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 INSTRUMENT-SPECIFIC CONTROLS 
          TABLE 24 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS OFFERED  BY KEY MARKET PLAYERS
          TABLE 25 MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 26 MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
           6.3.1 POLYMERASE CHAIN REACTION
                    6.3.1.1 Rising applications in proteomics and genomics to propel market
                                TABLE 27 MARKET FOR PCR,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.2 DNA SEQUENCING AND NGS
                    6.3.2.1 Increasing advancements in sequencing technologies to drive market
                                TABLE 28 MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.3 OTHER TECHNOLOGIES
                    TABLE 29 MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 MOLECULAR QUALITY CONTROL MARKET, BY ANALYTE TYPE (Page No. - 94)
    7.1 INTRODUCTION 
          TABLE 30 MOLECULAR QUALITY CONTROLS INDUSTRY, BY ANALYTE TYPE, 2021–2028 (USD MILLION)
    7.2 SINGLE-ANALYTE CONTROLS 
           7.2.1 RISING ADOPTION OF SINGLEPLEX ASSAYS IN HOSPITALS TO SUPPORT MARKET GROWTH
                    TABLE 31 SINGLE-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS
                    TABLE 32 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 MULTI-ANALYTE CONTROLS 
           7.3.1 GROWING PREFERENCE FOR COST-EFFECTIVE CONTROLS TO DRIVE MARKET
                    TABLE 33 MULTI-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS
                    TABLE 34 MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
 
8 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION (Page No. - 99)
    8.1 INTRODUCTION 
             TABLE 35 MOLECULAR QUALITY CONTROLS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 INFECTIOUS DISEASE DIAGNOSTICS 
           8.2.1 RISING INCIDENCE OF INFLUENZA, TB, AND HIV TO DRIVE MARKET
                    TABLE 36 NUMBER OF COVID-19 CASES, BY COUNTRY (FEBRUARY 2023)
                    TABLE 37 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 ONCOLOGY TESTING 
           8.3.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO PROPEL MARKET
                    TABLE 38 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                    TABLE 39 MARKET FOR ONCOLOGY TESTING, BY COUNTRY,  2021–2028 (USD MILLION)
    8.4 GENETIC TESTING 
           8.4.1 ABILITY TO DIAGNOSE RARE DISEASES TO SUPPORT MARKET GROWTH
                    TABLE 40 MARKET FOR GENETIC TESTING, BY COUNTRY,  2021–2028 (USD MILLION)
    8.5 OTHER APPLICATIONS 
          TABLE 41 MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
 
9 MOLECULAR QUALITY CONTROLS MARKET, BY END USER (Page No. - 108)
    9.1 INTRODUCTION 
          TABLE 42 MOLECULAR QUALITY CONTROLS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 DIAGNOSTIC LABORATORIES 
           9.2.1 INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES TO DRIVE MARKET
                    TABLE 43 MARKET FOR DIAGNOSTIC LABORATORIES,  BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 HOSPITALS 
           9.3.1 ABILITY TO CONDUCT LARGE VOLUME OF DIAGNOSTIC PROCEDURES TO PROPEL MARKET
                    TABLE 44 MARKET FOR HOSPITALS, BY COUNTRY,  2021–2028 (USD MILLION)
    9.4 IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS 
           9.4.1 ADVANCEMENTS IN MOLECULAR TECHNOLOGIES TO SUPPORT MARKET GROWTH
                    TABLE 45 MARKET FOR IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 ACADEMIC & RESEARCH INSTITUTES 
           9.5.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS TO DRIVE MARKET
                    TABLE 46 MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2021–2028 (USD MILLION)
    9.6 OTHER END USERS 
             TABLE 47 MARKET FOR OTHER END USERS, BY COUNTRY,  2021–2028 (USD MILLION)
 
10 MOLECULAR QUALITY CONTROLS MARKET, BY REGION (Page No. - 117)
     10.1 INTRODUCTION 
             TABLE 48 MOLECULAR QUALITY CONTROLS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 35 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT
             TABLE 49 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 50 NORTH AMERICA: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             TABLE 51 NORTH AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 52 NORTH AMERICA: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
             TABLE 53 NORTH AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 54 NORTH AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Growing number of accredited clinical laboratories to drive market
                                      FIGURE 36 US: NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023)
                                      TABLE 55 US: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 56 US: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 57 US: MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 58 US: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 59 US: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Rising funding investments for genomic research to propel market
                                      TABLE 60 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 61 CANADA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 62 CANADA: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 63 CANADA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 64 CANADA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.2.3 NORTH AMERICA: RECESSION IMPACT
     10.3 EUROPE 
             TABLE 65 EUROPE: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 66 EUROPE: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             TABLE 67 EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 68 EUROPE: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
             TABLE 69 EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 70 EUROPE: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Rising volume of diagnostic tests in clinical settings to drive market
                                      TABLE 71 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 72 GERMANY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 73 GERMANY: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 74 GERMANY: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 75 GERMANY: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Growth in life sciences industry to propel market
                                      TABLE 76 UK: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 77 UK: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 78 UK: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 79 UK: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 80 UK: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising prevalence of cancer and endocrine disorders to support market growth
                                      TABLE 81 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 82 FRANCE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 83 FRANCE: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 84 FRANCE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 85 FRANCE: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Rising incidence of age-associated chronic ailments to support market growth
                                      TABLE 86 ITALY: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 87 ITALY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 88 ITALY: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 89 ITALY: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 90 ITALY: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Increasing demand for prenatal and genetic testing to support market growth
                                      TABLE 91 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 92 SPAIN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 93 SPAIN: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 94 SPAIN: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 95 SPAIN: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.3.6 RUSSIA
                        10.3.6.1 Growing acceptance of molecular diagnostics-based personalized medicine to propel market
                                      TABLE 96 RUSSIA: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 97 RUSSIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 98 RUSSIA: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 99 RUSSIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 100 RUSSIA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 101 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 102 REST OF EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 103 REST OF EUROPE: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                        TABLE 104 REST OF EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 105 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.8 EUROPE: RECESSION IMPACT
     10.4 ASIA PACIFIC 
             FIGURE 37 ASIA PACIFIC: MARKET SNAPSHOT
             TABLE 106 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 107 ASIA PACIFIC: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             TABLE 108 ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 109 ASIA PACIFIC: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
             TABLE 110 ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 111 ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Established healthcare system and rising demand for high-quality IVD tests to drive market
                                      TABLE 112 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 113 JAPAN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 114 JAPAN: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 115 JAPAN: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 116 JAPAN: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Rising R&D investments for advanced molecular tests to drive market
                                      TABLE 117 CHINA: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 118 CHINA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 119 CHINA: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 120 CHINA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 121 CHINA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Rising need to secure NABL accreditations to support market growth
                                      FIGURE 38 INDIA: INCREASING NUMBER OF LABORATORIES WITH NABL ACCREDITATIONS  (2012–2020)
                                      TABLE 122 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 123 INDIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 124 INDIA: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 125 INDIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 126 INDIA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.4.4 AUSTRALIA
                        10.4.4.1 High prevalence of infectious diseases to fuel market
                                      TABLE 127 AUSTRALIA: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 128 AUSTRALIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 129 AUSTRALIA: MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 130 AUSTRALIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 131 AUSTRALIA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        TABLE 132 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 133 REST OF ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 134 REST OF ASIA PACIFIC: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                        TABLE 135 REST OF ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 136 REST OF ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.4.6 ASIA PACIFIC: RECESSION IMPACT
     10.5 LATIN AMERICA 
             TABLE 137 LATIN AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 138 LATIN AMERICA: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             TABLE 139 LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 140 LATIN AMERICA: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
             TABLE 141 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 142 LATIN AMERICA: MARKET, BY END USER, ‘ 2021–2028 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Improving healthcare infrastructure to support market growth
                                      TABLE 143 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 144 BRAZIL: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 145 BRAZIL: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 146 BRAZIL: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 147 BRAZIL: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth
                                      TABLE 148 MEXICO: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 149 MEXICO: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 150 MEXICO: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                                      TABLE 151 MEXICO: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 152 MEXICO: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                        TABLE 153 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 154 REST OF LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 155 REST OF LATIN AMERICA: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                        TABLE 156 REST OF LATIN AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 157 REST OF LATIN AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.5.4 LATIN AMERICA: RECESSION IMPACT
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
             10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 158 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 159 MIDDLE EAST & AFRICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY ANALYTE TYPE,  2021–2028 (USD MILLION)
                        TABLE 161 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 162 MIDDLE EAST & AFRICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 172)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
     11.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 
             FIGURE 39 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 40 MARKET SHARE ANALYSIS, BY KEY PLAYER (2022)
             TABLE 163 MARKET: INTENSITY OF COMPETITIVE RIVALRY
     11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 41 MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
     11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 42 MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
     11.7 COMPANY FOOTPRINT ANALYSIS 
             TABLE 164 MARKET: COMPANY FOOTPRINT ANALYSIS
             TABLE 165 MARKET: ANALYTE TYPE FOOTPRINT ANALYSIS
             TABLE 166 MARKET: APPLICATION FOOTPRINT ANALYSIS
             TABLE 167 MARKET: REGIONAL FOOTPRINT ANALYSIS
             TABLE 168 MARKET: END USER FOOTPRINT ANALYSIS
     11.8 COMPETITIVE SITUATION AND TRENDS 
             11.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 169 PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–JUNE 2023)
             11.8.2 DEALS
                        TABLE 170 DEALS (JANUARY 2020–JUNE 2023)
             11.8.3 OTHER DEVELOPMENTS
                        TABLE 171 OTHER DEVELOPMENTS (JANUARY 2020–JUNE 2023)
 
12 COMPANY PROFILES (Page No. - 189)
     12.1 KEY PLAYERS 
(Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View)*
             12.1.1 LGC LIMITED
                        TABLE 172 LGC LIMITED: BUSINESS OVERVIEW
                        FIGURE 43 LCG LIMITED: COMPANY SNAPSHOT (2022)
             12.1.2 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 173 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
             12.1.3 BIO-RAD LABORATORIES, INC.
                        TABLE 174 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             12.1.4 MICROBIOLOGICS, INC.
                        TABLE 175 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW
             12.1.5 ABBOTT LABORATORIES
                        TABLE 176 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 46 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             12.1.6 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 177 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             12.1.7 ZEPTOMETRIX, LLC
                        TABLE 178 ZEPTOMETRIX, LLC: BUSINESS OVERVIEW
             12.1.8 QUIDELORTHO CORPORATION
                        TABLE 179 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 48 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.9 QNOSTICS
                        TABLE 180 QNOSTICS: BUSINESS OVERVIEW
             12.1.10 MAINE MOLECULAR QUALITY CONTROLS, INC.
                        TABLE 181 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW
             12.1.11 RANDOX LABORATORIES LTD.
                        TABLE 182 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
             12.1.12 DANAHER CORPORATION
                        TABLE 183 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.13 BIO-TECHNE CORPORATION
                        TABLE 184 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 50 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.14 FORTRESS DIAGNOSTICS
                        TABLE 185 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW
             12.1.15 MICROBIX BIOSYSTEMS
                        TABLE 186 MICROBIX BIOSYSTEMS: BUSINESS OVERVIEW
                        FIGURE 51 MICROBIX BIOSYSTEMS: COMPANY SNAPSHOT (2022)
             12.1.16 GRIFOLS, S.A.
                        TABLE 187 GRIFOLS, S.A.: BUSINESS OVERVIEW
                        FIGURE 52 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022)
             12.1.17 ANCHOR MOLECULAR
                        TABLE 188 ANCHOR MOLECULAR: BUSINESS OVERVIEW
             12.1.18 SPEEDX PTY. LTD.
                        TABLE 189 SPEEDX PTY. LTD.: BUSINESS OVERVIEW
             12.1.19 SEEGENE INC.
                        TABLE 190 SEEGENE INC.: BUSINESS OVERVIEW
                        FIGURE 53 SEEGENE INC: COMPANY SNAPSHOT (2022)
             12.1.20 HELENA LABORATORIES CORPORATION
                        TABLE 191 HELENA LABORATORIES CORPORATION: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 SERO AS
                        TABLE 192 SERO AS: BUSINESS OVERVIEW
             12.2.2 VIRCELL, S.L.
                        TABLE 193 VIRCELL, S.L.: BUSINESS OVERVIEW
             12.2.3 STRECK LLC
                        TABLE 194 STRECK LLC.: BUSINESS OVERVIEW
             12.2.4 SUN DIAGNOSTICS, LLC
                        TABLE 195 SUN DIAGNOSTICS, LLC: BUSINESS OVERVIEW
             12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
                        TABLE 196 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW
 
*Details on Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 273)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved three major activities in estimating the size of the molecular quality controls market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Clinical and Laboratory Standards Institute (CLSI), World Health Organization (WHO), Clinical Laboratory Improvement Amendments (CLIA), National Accreditation Board for Testing and Calibration Laboratories (NABL), Centers for Disease Control and Prevention (CDC), Organisation for Economic Co-operation and Development (OECD), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the molecular quality controls market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the smart pills market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

Breakdown of Primary Interviews

Molecular Quality Controls Market Size, and Share

Note 1: Companies are classified into tiers based on their total revenue. As of 2021: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

Note 2: C-level executives include CEOs, COOs, CTOs, and VPs. 

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches have been used to estimate and validate the size of the molecular quality controls market and to estimate the size of various other dependent submarkets in the overall molecular quality controls market.

The research methodology used to estimate the market size includes the following details:

  • The market value of molecular quality controls for infectious disease diagnostics, oncology testing, and genetic testing applications have been extracted from the repository and validated through secondary and primary research.
  • The market shares of the infectious disease diagnostics, oncology testing, and genetic testing applications in the global molecular quality controls market were derived and added up to reach the market value.
  • This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives.
  • The bottom-up approach has been applied to different regions, and other segments of the molecular quality controls market. All percentage shares, splits, and breakdowns have been determined by using secondary sources and verified through primary sources.
  • All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
  • This data is consolidated and added with detailed inputs and analysis from MarketsandMarkets, and presented in this report.

Molecular Quality Controls Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

Market Definition

Molecular quality control is a quality control material made up of synthetic or biological components (such as whole blood, serum, plasma, urine, and spinal fluid sourced from human or animal origin) that can be used to evaluate and monitor analytical processes during molecular testing procedures for clinical diagnostics and research applications. The focus of these quality controls is to test the molecular diagnostic products in order to identify defects and report them to management authorities.

Key Stakeholders

  • Molecular quality control manufacturers, vendors, and distributors
  • Manufacturers and distributors of molecular diagnostic instruments and assays
  • Group purchasing organizations (GPOs)
  • Original equipment manufacturers (OEMs)
  • Diagnostic laboratories
  • Hospitals and clinics
  • Contract research organizations (CROs)
  • IVD manufacturers and distributors
  • Blood banks
  • Research institutes and government organizations
  • Market research and consulting firms
  • Contract manufacturing organizations (CMOs)
  • Venture capitalists

Report Objectives

  • To define, describe, segment, and forecast the global molecular quality controls market by product, analyte type, application, end user, and region
  • To provide detailed information about the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall molecular quality controls market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key market players
  • To forecast the size of the market segments in five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their core competencies2 in terms of key market developments, product portfolios, and financials
  • To track and analyze competitive developments such as product launches, partnerships, collaborations, mergers, and acquisitions are the principal growth strategies adopted by market players in this period

Available Customizations

MarketsandMarkets offers the following customizations for this market report:

  • Detailed analysis and profiling of additional market players (up to 5)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 6900
Published ON
Jul, 2023
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Molecular Quality Controls Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback